Financial Comparison: Alvotech (NASDAQ:ALVO) and Anixa Biosciences (NASDAQ:ANIX)

Anixa Biosciences (NASDAQ:ANIX) and Alvotech (NASDAQ:ALVO) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Valuation and Earnings

This table compares Anixa Biosciences and Alvotech”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anixa Biosciences	$210,000.00	524.71	-$10.93 million	($0.32)	-9.91
Alvotech	$588.90 million	2.40	$27.92 million	($0.61)	-7.68

Alvotech has higher revenue and earnings than Anixa Biosciences. Anixa Biosciences is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Anixa Biosciences and Alvotech, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anixa Biosciences	1	1	3	0	2.40
Alvotech	2	1	4	0	2.29

Anixa Biosciences presently has a consensus target price of $8.00, indicating a potential upside of 152.37%. Alvotech has a consensus target price of $8.50, indicating a potential upside of 81.43%. Given Anixa Biosciences’ stronger consensus rating and higher probable upside, equities analysts plainly believe Anixa Biosciences is more favorable than Alvotech.

Profitability

This table compares Anixa Biosciences and Alvotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Anixa Biosciences	N/A	-76.59%	-67.80%
Alvotech	-36.31%	N/A	-11.73%

Institutional & Insider Ownership

29.1% of Anixa Biosciences shares are held by institutional investors. 26.4% of Anixa Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Anixa Biosciences has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500. Comparatively, Alvotech has a beta of 0.2, indicating that its share price is 80% less volatile than the S&P 500.

Summary

Anixa Biosciences beats Alvotech on 8 of the 14 factors compared between the two stocks.

About Anixa Biosciences

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

About Alvotech

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.